Floatz logo

MITOMYCIN C

Appendiceal Cancer

National Cancer Institute (NCI)Small moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Appendiceal Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
Sodium Thiosulfate
National Cancer Institute (NCI)
Phase 2B
Nilotinib
National Cancer Institute (NCI)
Phase 2B
Floxuridine
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Evomela
University of Kansas Medical Center
Phase 2CCC

View all 26 →

Same molecule, other indications

MITOMYCIN C is also rated in:

colorectal carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
appendix carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
peritoneal carcinomatosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →